Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Feb 22;15(2):e35305.
doi: 10.7759/cureus.35305. eCollection 2023 Feb.

Focal Crescentic Glomerulonephritis Following COVID-19 Viral Vector Vaccination

Jacqueline M Wisnik-Rainville  1   2 , Robert Czyzewski  3   2 , Cynthia Demola  3 , Konrad Czyzewski  2
Affiliations
Case Reports

Focal Crescentic Glomerulonephritis Following COVID-19 Viral Vector Vaccination

Jacqueline M Wisnik-Rainville et al. Cureus. .

Abstract

Vaccination is a vital tool aimed at curbing the COVID-19 pandemic, and the FDA has authorized several vaccines for emergency use to combat COVID-19. Our patient presented with acute kidney injury two weeks after receiving the first dose of the COVID-19 Janssen (Johnson & Johnson) vaccine. Renal biopsy confirmed focal crescentic glomerulonephritis. The patient has been unable to achieve remission after diagnosis and is now a candidate for a kidney transplant. In conclusion, this case report provides insight into the possible relationship between glomerular disease following COVID-19 Janssen (Johnson & Johnson) vaccination. Based on this presented case, new-onset or relapse of glomerular diseases presenting post-COVID-19 vaccination should be observed as a possible adverse event to large-scale COVID-19 vaccination.

Keywords: acute kidney injury; covid-19; covid-19 vaccination; end stage kidney disease; glomerular disease; glomerulonephritis; kidney transplant; sars-cov2; vaccination.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

References

    1. COVID Data Tracker. [ Dec; 2022 ]. 2022. https://covid.cdc.gov/covid-data-tracker https://covid.cdc.gov/covid-data-tracker
    1. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. Polack FP, Thomas SJ, Kitchin N, et al. N Engl J Med. 2020;383:2603–2615. - PMC - PubMed
    1. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. Baden LR, El Sahly HM, Essink B, et al. N Engl J Med. 2021;384:403–416. - PMC - PubMed
    1. Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19. Sadoff J, Gray G, Vandebosch A, et al. N Engl J Med. 2021;384:2187–2201. - PMC - PubMed
    1. New-onset and relapsed kidney histopathology following COVID-19 vaccination: a systematic review. Wu HH, Kalra PA, Chinnadurai R. Vaccines (Basel) 2021;9 - PMC - PubMed

Publication types

LinkOut - more resources